Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech VC (Venture Capital) Funds in Belgium in April 2025

Last updated: Apr 2025 A list of 50 VC (Venture Capital) funds that invest in Biotech startups based in Belgium. We rank investors based on the number of investments they made in Biotech companies from Belgium. We update this investor list every month.

Top 50 Biotech VC (Venture Capital) Funds in Belgium in April 2025

Investor	Biotech Belgium investments
S.R.I.W.	14
PMV	14
V-Bio Ventures	13
Qbic Fund	11
Meusinvest (Noshaq)	11
Gemma Frisius Fund	10
VIB	10
Vives Louvain Technology Fund	9
Gimv	9
Limburgse Reconversie Maatschappij	8
Capricorn Partners	7
Vesalius Biocapital Partners	6
Sambrinvest	6
EQT Life Sciences	5
Newton Biocapital	5
Droia Ventures	4
KBC	4
Spinventure	4
Boehringer Ingelheim Venture Fund	4
Baekeland Funds	4
Omnes Capital	4
New Science Ventures	3
Fountain Healthcare Partners	3
UCB Ventures	3
Fund+	3
AdBio partners	3
VIVES Funds	3
Inventures SA	3
BioGeneration Ventures	3
Theodorus III	3
Nivelinvest	3
Agri Investment Fund	3
Novo Holdings	2
Sofinnova Partners	2
Eli Lilly	2
Innovation Fund	2
Spreds	2
Forbion Capital Partners	2
M Ventures	2
High-Tech Gruenderfonds	2
SFPIM	2
Pontifax	2
Thuja Capital	2
GoBeyond	2
SFPI-FPIM	2
Quest for Growth	2
Ackermans & van Haaren	2
Johnson & Johnson Innovation – JJDC	2
Vinnof	2
Merieux Developpement	2

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the SociÃ©tÃ© RÃ©gionaledâ€™Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.

Investment focus

Biotechnology, Health Care, Manufacturing
Funding Round, Series A, Series B
Belgium, United States, Spain

Portfolio highlights

Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
Santero Therapeutics — This is the homepage of the website

Do and dare company

Investment focus

Software, Biotechnology, Health Care
Series A, Seed, Series B
Belgium, United States, The Netherlands

Portfolio highlights

Nobi — Fall detection for the elderly at your home or in a residential care center with the smart Nobi lamp. Nobi ensures that you can be helped quickly.
Apideck — Integrate and monitor APIs at warp speed. Apideck is the fastest way for developers to build integrations. Connect new APIs in minutes instead of days.
Swave Photonics — Swave develops Spatial Computing, Holography, holographic chips, and holograms in the HXR chip to create 3D augmented and virtual reality and HUD Heads Up Displays

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
Belgium, France, United Kingdom

Portfolio highlights

ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.

Investment focus

Biotechnology, Software, Health Care
Seed, Funding Round, Series A
Belgium

Portfolio highlights

Pleevi — AI powered smart charging APIs to charge fleet more cost-efficient and cleaner on professional sites
Weavely — Design forms in Figma - publish with Weavely. We turn your visual ideas into interactive, web-based forms.
Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.

Noshaq offers financial services to help businesses develop.

Investment focus

Biotechnology, Health Care, Medical
Series A, Seed, Funding Round
Belgium, France, Germany

Portfolio highlights

TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
Veoware — More coverage, shorter revisit time. Increasing target collection frequency through modular next-gen actuator technology.
Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.

Gemma Frisius Fund KU Leuven is a seed capital fund that aims to stimulate the creation and growth of university related spin-off companies.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series B, Series A
Belgium, France, United Kingdom

Portfolio highlights

DName-iT — DName-iT is a genetic analysis tool that offers DNA-based barcode labeling technology and a software platform that can ensure reliable, cost-effective NGS specimen identification.
Protealis — Sustainable plant proteins for Europe
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

Strategic research in on life sciences and biotechnology

Investment focus

Biotechnology, Pharmaceutical, Health Care
Series A, Series B, Funding Round
Belgium, Brazil, Denmark

Portfolio highlights

Protealis — Sustainable plant proteins for Europe
Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Belgium, France, United States

Portfolio highlights

BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Gimv, a trusted European investment company, helps mid-market businesses create sustainable value through growth capital and expertise across diverse sectors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Funding Round, Private Equity
Belgium, United States, France

Portfolio highlights

Curana — Curana is a manufacturer of bike equipment and accessories.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Oxygen for growth - LRM

Investment focus

Information Technology, Software, Biotechnology
Funding Round, Series A, Seed
Belgium, United States, The Netherlands

Portfolio highlights

Cumul.io — Create powerful dashboards in minutes. Share with your teams, or integrate in your platform. Drive growth in your business today!
ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
Raw Stadia — Raw Stadia is a sports technology company that specializes in surface player interactions.

Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds

Investment focus

Biotechnology, Health Care, Software
Funding Round, Series B, Series A
Belgium, United States, The Netherlands

Portfolio highlights

InsectSense — MIMICKING HOW INSECTS SENSE | Biomimetic technology based on the sensing mechanism of insects. A deeptech platform that applies synthetic biology, microfluidics and is powered by machine learning.
Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
Econic Technologies — At Econic, we are pioneering the transformation of CO2 into high-performance materials that shape a better future for all.

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
Belgium, Germany, The Netherlands

Portfolio highlights

CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
Caresyntax — Caresyntax is the only enterprise-scale surgical data solution you need to make surgery smarter, safer, and more profitable.
Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.

Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Series A, Series B
Belgium, France, Spain

Portfolio highlights

AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

XyloCor Therapeutics — XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.

Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round, Seed
Belgium, Japan, France

Portfolio highlights

AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.

Investment focus

Biotechnology, Medical, Therapeutics
Series A, Series B, Series C
United States, Belgium, The Netherlands

Portfolio highlights

Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
Alesta Therapeutics — Alesta Therapeutics pioneers innovative small molecule therapies for rare diseases, including hypophosphatasia and Charcot-Marie-Tooth

KBC Private Equity - the investment company of KBC Group - provides development capital and finances buy-outs to medium-sized companies in Belgium and in Central and Eastern Europe, KBC's home markets.Boasting an experienced team of 28 people, it has more than 60 active investments in portfolio with a market value in excess of EUR 400million.KBC Private Equity aims to become one of the leading private equity providers on KBC Group's home markets. As an active shareholder with a long-term perspective, KBC Private Equity is involved in taking strategic decisions and providing support to management teams.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Series A, Series B
Belgium, United States, Luxembourg

Portfolio highlights

ELIS — Elis is a multi-services group in Europe and Brazil, specialized in the rental and maintenance of professional clothing and textile articles, as well as hygiene appliance and well-being services. With more than 19,000 employees spread across 13 countries, Elis consolidated turnover in 2014 was €1.331 billion and consolidated EBITDA reached €429million. Benefiting from more than a century of experience, Elis today services more than 240 000 businesses of all sizes in the hotel, catering, healthcare, industry, retail and services sectors, thanks to its network of nearly 300 production and distribution centers and 13 clean rooms, which guarantees it an unrivalled proximity to its clients.
Setle — During the renovation process, Settle assists in helping to make better judgments. Settle's goal is to increase renovation transparency. From increasing the energy efficiency of your home to getting the most out of your housing budget.
MICLEDI Microdisplays — MICLEDI Microdisplays is an experienced executive in the semiconductor industry,

Spinventure supports the creation of spin-off companies that aim to industrialize and commercialize the result of scientific research. Spinventure was born from a collaboration between MEUSINVEST and the University of Liège. It is headquartered in Angleur, Belgium.

Investment focus

Health Care, Biotechnology, Medical
Series A, Funding Round
Belgium

Portfolio highlights

Dim3 — Improve patients outcome - Deliver actionable insights - Save healthcare costs
Elysia — Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
Convert Pharmaceuticals — Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors.

Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

Baekeland Funds is a seed capital fund formed to invest in companies developed at the University of Ghent.

Investment focus

Biotechnology, Hardware, Software
Funding Round, Series B, Series C
Belgium

Portfolio highlights

Caliopa — Caliopa NV develops and markets silicon photonics based optical transceivers for the data and telecommunications markets. The company was incorporated in 2010 and is based in Zwijnaarde, Belgium.
Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Trinean — Unchained Labs helps biologics & gene therapy researchers break free from tools that don't cut it. Crank up your research with our problem-solving products.

Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.

Investment focus

Biotechnology, Software, Health Care
Series A, Funding Round, Series B
France, Germany, United States

Portfolio highlights

Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
The Exploration Company — For Space & Non-Space Industries.

New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series D
United States, United Kingdom, Belgium

Portfolio highlights

Glydways — Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs.
Vuv Analytics — VUV Analytics was incorporated in Austin, TX in December 2009, as a spin-off from a semiconductor equipment company. The five founders bring with them critical and unique know-how related to the hardware, software, analysis, intellectual property, and marketing associated with VUV technologies. The team's past success in pioneering VUVreflectometry for use in the semiconductor metrology field yielded several key market wins and an extensive IP portfolio, including 32 issued patents and 12 pending patents.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
Ireland, United States, France

Portfolio highlights

MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
Mainstay Medical — Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions.
XyloCor Therapeutics — XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.

UCB Ventures is a €150 million strategic corporate venture fund

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Belgium, Spain

Portfolio highlights

ViaNautis — Precision Solutions
Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Switch Therapeutics — Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs (CASi).

Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
Belgium, United States, Spain

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Funding Round
France, Spain, Belgium

Portfolio highlights

Cephagenix — Cephagenix focuses on identifying and developing new, effective migraine therapies.
Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact.

Investment focus

Biotechnology, Therapeutics, Farming
Seed, Series A
Belgium, France

Portfolio highlights

BiocSol — BiocSol focus on sustainable microbial-based crop protection.
Generare — Harness the ingenuity of nature to transform small molecule discovery
ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.

Inventures is a European venture capital fund that builds a better world through a portfolio of investments in sustainable businesses.The firm has two funds: Inventures I & Inventures II.Inventures was created to support early stage smart and innovative European businesses, to support sustainable job growth and empower entrepreneurs.Inventures empowers citizenship co-investments through a crowdfunding platform, MyMicroInvest.

Investment focus

Health Care, Manufacturing, Biotechnology
Series A, Seed, Funding Round
Belgium, France, United Kingdom

Portfolio highlights

BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
myskillcamp — Myskillcamp is a digital learning platform and educational design support service. Myskillcamp supports their customers in the digital transformation of their company and the launch of their Digital Learning project. From the audit of needs to the design of engaging educational devices, through a pilot phase, they make a point of honor to adapt thedigital to the specificities of each and give it meaning.With their online platform, businesses can manage their learner communities and connect all their partners in one place. Their tool also allows businesses to structure training spaces by skills, trades, brands within camps. In parallel, businesses can create educational content from scratch, select a map in their marketplace, or plan sessions in-class. Businesses can organize the distribution of their training to a single learner or to a whole group.
Octave — A sustainable, cost-effective and reliable energy storage system with second-life batteries from electric vehicles.

Shaping new life-science ventures.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Funding Round, Seed
The Netherlands, United States, Belgium

Portfolio highlights

Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.

Investment focus

Health Care, Life Science, Medical
Funding Round, Seed, Series A
Belgium, Canada, France

Portfolio highlights

DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
HYPNO VR — HypnoVR is a virtual reality software for anesthesia, treatment of pain, and anxiety. It was founded in 2016 and is based in Strasbourg, France.
Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.

Nivelinvest is a venture capital firm based in Belgium that finances seed stage investments of Small and Medium Enterprises.

Investment focus

Biotechnology, iOS, Construction
Series A, Seed, Funding Round
Belgium, United States

Portfolio highlights

e-peas — Ready to make your device energy autonomous with our state-of-art energy harvesting solutions? Phone: (+32) 10 77 12 30, sales@e-peas.com
A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

AgroSavfe nv, a Belgium-based agro-biotech company

Investment focus

Biotechnology, Chemical, Veterinary
Series B, Series A, Seed
Belgium

Portfolio highlights

Animab — Animal Health Company
BiocSol — BiocSol focus on sustainable microbial-based crop protection.
Aphea.Bio — . .sustainableagriculture-section {. backgroundcolor: fff;. boxshadow: 0 0.40rem 0.40rem rgba(0, 0, 0, 0.25);. display: flex;. flexdirection: column;. overflow: hidden;. backgroundsize: cover;. }.. .herobanner {. display: flex;. flexdirection: column;. position: relative

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
Latent Labs — Latent Labs is making biology programmable to transform health and sustainability for the benefit of all.We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizingexisting enzymes, and advancing genetic engineering.Contact us to work with us today.
Berry Street — Nutrition therapy by registered dietitians covered by insurance.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, United Kingdom, Canada

Portfolio highlights

Maxion Therapeutics — Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets.
Ampersand Biomedicines — Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

Chemical, Advanced Materials, Cosmetics, Recycling, CleanTech, Plastics and Rubber Manufacturing, Nanotechnology, Biosciences

Investment focus

Health Care, Manufacturing, Information Technology
Funding Round, Seed, Series A
Belgium, France, Luxembourg

Portfolio highlights

Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
Fyteko — For a more sustainable agriculture
Graftys — Graftys, an Aix-en-Provence, France-based early stage company focused on advanced bone biologics.

We empower high-potential entrepreneurship and democratize venture capital. Discover promising start-ups & SMEs and invest alongside business angels.

Investment focus

Health Care, Information Technology, Food and Beverage
Series A, Seed, Series B
Belgium, France

Portfolio highlights

Opinum — What is Opinum Data Hub? Our Data Hub is a secured Cloud-based platform that allows energy and environmental actors to centralise, enhance, analyse, and share data.
Digiteal — Digiteal offers a wide range of services for e-invoice presentment, electronic payments and open banking.
NietsCo — NietsCo. is the home of Botaniets Gin 0.0%, a leading selection of alcohol-free products, carefully distributed to the world's best restaurants, concept stores, shops and consumers.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Numab — Numab Therapeutics AG
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
NovoLINC — NovoLINC is a pioneering startup that provides thermal interface solutions. It develops a distinctive system of nanostructured materials and a proprietary manufacturing process with the objective of transforming thermal management.
TRIMTECH Therapeutics — TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD).

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

AICA SA — AICA believes programming robots should be at everyone's reach. We combine Artificial Intelligence & an intuitive interface, to help you relocate your production.
ctrl+s — High resolution insights into the deep supply chain are the building blocks for every substantive sustainability strategy and effective decarbonization.
Akribion Genomics — Specific, versatile, effective RNA-guided cell depletion

SFPIM investment firm that invests in technology and infrastructure.

Investment focus

Biotechnology, PaaS, SaaS
Series A, Series C
Belgium, France

Portfolio highlights

PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
MICLEDI Microdisplays — MICLEDI Microdisplays is an experienced executive in the semiconductor industry,

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
Indapta Therapeutics — Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.

Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Series A, Seed
The Netherlands, Belgium, United States

Portfolio highlights

Pan Cancer — Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer.
Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
Artica Therapeutics — Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Investment focus

Information Technology, Medical, Software
Funding Round, Seed, Series A
Switzerland, Germany, United Kingdom

Portfolio highlights

LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.

The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Series B, Series A
Belgium, United States, France

Portfolio highlights

Cohabs — We create sustainable & community-driven shared homes around the world for young workers and interns. Join our community.
Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.

Quest for Growth (QGPLF) is an Internet company located in 19 Lei, Leuven, Flanders, Belgium.

Investment focus

Biotechnology, Hardware, Software
Funding Round, Series B, Series C
Belgium, France, The Netherlands

Portfolio highlights

Qpinch — Our patented QHT - Qpinch Heat Transformer - technology recovers and transforms waste heat into carbon neutral process heat.
Finquest — Tap into the largest private company database in the world to change the way you find and connect with M&A targets using Data, AI, & People.
Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.

Ackermans & van Haaren is a diversified group active in 5 segments: Marine Engineering & Infrastructure; Private Banking; Real Estate, Leisure & Senior Care; Energy & Resources; Development Capital. Marine Engineering & Infrastructure: DEME, one of the largest dredging companies in the world - Algemene Aannemingen Van Laere,a leading contractor in Belgium. Ackermans & van Haaren is an independent and diversified group aiming at creating shareholder value through long-term investments in a limited number of companies with growth potential on an international level.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
Belgium, India

Portfolio highlights

AstriVax — AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
Medikabazaar — Medikabazaar is an online B2B marketspace for medical supplies and equipment. They are a single point of contact for all product-based needs, enabling medical institutions and individual practitioners alike to cut down on operational costs and making the best global brands available locally, all aided with the miracle that goes by the name oftechnology. They are connected with more than 50,000 medical establishments, 1,50,000 Independent Practitioners, and have partnered with 13,000+ suppliers all over India including ones in Tier 2, Tier 3 cities, and remoter locations to establish a strong foothold in India and simultaneously earn the respect of our clients. With the power of technology, we organized a haywire market in a country with perhaps the largest and most complex geographical structure in the world for this purpose. Our last-mile delivery system and 26 strategically placed Fulfilment Centres across India enable us to deliver essential medical supplies to healthcare facilities and help them nurture quality and timely patient care. With our first international office in the Middle East, we are transcending boundaries to deliver care, everywhere.
Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
TECLens — TECLens is creating a crosslinking technology that may accurately fix vision issues in healthy eyes as well as treat keratoconus. It provides patients with presbyopia with the ability to regain their ability to read at a distance, controls children's progressive myopia, corrects adult vision problems like hyperopia and low-order myopia, andmore.
Perceive Pharma — Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Vinnof is a venture capital firm that offers seed capital to innovative, early-stage startups based in Flanders, Belgium.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
Belgium, United Kingdom

Portfolio highlights

Apitope — Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of productcandidates developed with its proprietary platform technology.
Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Okapi Sciences — Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination ofindividuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.

Mérieux Développement is specialized in Growth and Venture capital transactions in the healthcare and nutrition sectors. We support companies with products or services offering true differentiation and capacity to create substantial value over the long term. Our investment team, based in Europe and North America, brings its expertise andinternational network to help entrepreneurs disrupt and grasp substantial market opportunities. Mérieux Développement is an affiliate of Institut Mérieux, which employs approximately 17,000 employees worldwide, with consolidated revenues exceeding 2.5 billion Euros in 2017.

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Series C, Series B
France, United States, Belgium

Portfolio highlights

SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
TISSIUM — TISSIUM is creating the future of tissue reconstruction. Learn more about our novel solutions based on our proprietary platform of biomorphic programmable polymers.
Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Investors by industry